| 1 |
33270185 | Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention. | 2021 Apr |
1 |
| 2 |
34164723 | The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention. | 2021 Nov |
2 |
| 3 |
34351918 | PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study. | 2021 |
4 |
| 4 |
34764653 | Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population. | 2021 |
1 |
| 5 |
32702814 | CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019. | 2020 Jul 17 |
2 |
| 6 |
32862511 | Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. | 2020 Dec |
2 |
| 7 |
30520344 | Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. | 2019 Jan |
1 |
| 8 |
30891852 | Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. | 2019 Jun |
6 |
| 9 |
29411531 | Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. | 2018 Jun |
2 |
| 10 |
28076455 | Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients. | 2017 Jan 9 |
2 |
| 11 |
26573179 | PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. | 2016 Apr |
3 |
| 12 |
25297118 | Significant interethnic differencies in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. | 2015 Jan |
2 |
| 13 |
26099919 | The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. | 2015 Aug |
2 |
| 14 |
26309584 | Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention. | 2015 |
2 |
| 15 |
24504666 | Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants. | 2014 Aug |
1 |
| 16 |
24566733 | Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. | 2014 Jun |
1 |
| 17 |
25329996 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. | 2014 |
3 |
| 18 |
22974728 | Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. | 2013 Apr 30 |
1 |
| 19 |
23150151 | Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. | 2013 May |
4 |
| 20 |
23333143 | Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. | 2013 Feb 26 |
2 |
| 21 |
23608957 | Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. | 2013 Aug |
1 |
| 22 |
23993903 | PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. | 2013 Oct |
7 |
| 23 |
24080149 | Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers. | 2013 Nov |
4 |
| 24 |
24378836 | Genetic and nongenetic factors influencing the response to clopidogrel. | 2013 Dec |
2 |
| 25 |
22103858 | Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. | 2012 Feb 20 |
5 |
| 26 |
22115701 | Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. | 2012 Apr |
2 |
| 27 |
22368149 | Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. | 2012 Apr 1 |
2 |
| 28 |
22374717 | Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. | 2012 Nov |
4 |
| 29 |
22427735 | Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. | 2012 |
2 |
| 30 |
22428615 | The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. | 2012 Aug |
4 |
| 31 |
22462746 | CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. | 2012 Apr |
1 |
| 32 |
22520065 | Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. | 2012 Jul |
9 |
| 33 |
22723959 | Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. | 2012 |
2 |
| 34 |
23346768 | Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients. | 2012 Dec |
5 |
| 35 |
23363670 | [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome]. | 2012 Nov |
1 |
| 36 |
21170047 | Paraoxonase-1 is a major determinant of clopidogrel efficacy. | 2011 Jan |
5 |
| 37 |
21527445 | No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. | 2011 Jul |
4 |
| 38 |
21592545 | Pharmacogenomics of clopidogrel: evidence and perspectives. | 2011 Oct |
5 |
| 39 |
21685174 | Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. | 2011 Aug 1 |
4 |
| 40 |
21692977 | Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. | 2011 Aug |
1 |
| 41 |
21881565 | Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. | 2011 Oct |
2 |
| 42 |
21918510 | Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. | 2011 Oct |
3 |
| 43 |
21972404 | CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. | 2011 Oct 1 |
3 |
| 44 |
22008470 | Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. | 2011 Dec |
7 |
| 45 |
22010185 | Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy. | 2011 Oct 1 |
1 |
| 46 |
22089343 | Unveiling the mysteries of clopidogrel metabolism and efficacy. | 2011 Dec |
1 |
| 47 |
25083217 | Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. | 2011 Dec |
3 |